Other

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Sorbonne Université

Assistance Publique-hopitaux De Paris

UniversitÉ Paris Descartes

Université Paris Diderot-Paris 7

Université Pierre Et Marie Curie - Upmc

UniversitÉ De Paris

Inserm (institut National De La Sante Et De La Recherche Medicale)

Inserm

Pepkon

Philippe Karoyan

Santos A Susin

Pierre Launay

Helene Merle-Beral

Jose-Alain Sahel

Florian Sennlaub

Xavier Guillonneau

Michael Housset

Hélène Merle-Beral

José-Alain Sahel

The present invention relates to a compound or a pharmaceutical salt thereof comprising a hexapeptide sequence of formula (I), its method of synthesis and its use in anticancer therapy. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Compounds and pharmaceutical use thereof in the treatment of cancer

The present invention relates to cyclic peptides mimetics of the C-terminal binding domain of TSP-1. The present invention also relates to the use of these cyclic peptides as agonists of CD47 and their ability to trigger programmed cell death (PCD). The present invention further relate to a pharmaceutical composition for use in the treatment of diseases associated with defects in PCD such as cancers and immunological disorders (including chronic inflammation) and comprising at least one cyclic peptide according to the invention.

Agonist agents of CD47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death

Disclosed are agents activating CD47 and their use in the treatment of inflammation, in particular non-resolving low grade inflammation, characterized by chronic MP infiltration, such as age-related macular degeneration. Also disclosed are pharmaceutical compositions, medicaments and kits including the agents.

Agents that activate CD47 and their use in the treatment of inflammation

The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Method and pharmaceutical composition for use in the treatment of cancer

The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Growing community of inventors

Paris, France

Philippe Karoyan